NCT05096117 - Human Laboratory Study of ASP8062 for Alcohol Use Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

March 22, 2023

Study Completion Date

March 22, 2023

Conditions

Alcohol Use DisorderAlcohol DrinkingAlcohol Use Disorder (AUD)

Interventions

DRUG

ASP8062

ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks

DRUG

Placebo

1 x per day for 6 weeks

Trial Locations (3)

80045

University of Colorado, Aurora

90095

University of California Los Angeles, Los Angeles

02912

Brown University, Providence